Magnetic sphincter augmentation at the time of bariatric surgery: an analysis of the MBSAQIP.

Publication/Presentation Date

3-1-2021

Abstract

BACKGROUND: Magnetic sphincter augmentation (MSA) has gained popularity as a treatment for gastroesophageal reflux disease (GERD). The role of MSA in treating GERD in metabolic and bariatric surgery (MBS) patients at the time of primary MBS is unknown.

OBJECTIVE: To determine the short-term outcomes of MSA placed at the time of MBS.

SETTING: National database, United States.

METHODS: We queried the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database for MSA performed at time of the sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) for the years 2017-2018. A propensity adjusted analysis was performed to assess 30-day outcomes of patients who had MSA placed versus those who did not.

RESULTS: There were 319,580 patients who underwent MBS in the study period. Twenty-four patients had MSA at time of surgery. These patients did not have a higher reported rate of preoperative GERD (P = .93). Six patients (25%) with MSA had a RYGB; the other 18 patients (75%) patients had SG (P < .001). Operative times were similar between the groups and there was no difference in length of stay. After propensity matched analysis (with 24 patients in each arm), patients who underwent an MSA had shorter discharge times (1.4 days [.8] versus 2.0 [.9], P = .012).

CONCLUSION: MSA is safe in the short term in MBS. There is no difference in major morbidity or mortality and operative times are similar in MSA patients. The long-term efficacy of this practice is unknown.

Volume

17

Issue

3

First Page

555

Last Page

561

ISSN

1878-7533

Disciplines

Medicine and Health Sciences

PubMedID

33272856

Department(s)

Department of Surgery, Department of Surgery Residents, Fellows and Residents

Document Type

Article

Link to Full Text

Share

COinS